MetaCap

IRulya Therapeutics Earnings

NASDAQ: IRLAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

39.88-0.06 (-0.15%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IRulya Therapeutics earnings summary

In its most recent report on Nov 13, 2026 (Sep/2026), IRLA posted EPS of $-1.12 versus the $-0.84 consensus estimate, a negative surprise of 33.3%. IRulya Therapeutics beat the consensus EPS estimate in 1 of the last 2 quarters, with a median surprise of +3045.4%. Quarterly EPS is down 100.9% from the same quarter a year earlier.

Across the last 3 reports, IRLA shares moved an average of 0.2% (in either direction) in the first trading session after results, rising 2 times and falling 1 times.

Summary generated from market data by MetaCap's automated system. Methodology

IRLA earnings history

IRulya Therapeutics reported EPS versus estimates
Report dateEPS est.EPS actualSurprisePrice reaction
Nov 13, 2026$-0.84$-1.12-33.3%+0.2%
Nov 11, 2026$-0.83$50.00+6124.1%+0.2%
Aug 14, 2026—$-12.31—-0.3%
May 11, 2026—$2.88——
Feb 12, 2026—$120.32——
Nov 12, 2025—$-49.83——
Aug 11, 2025—$-68.75——
May 13, 2025—$-3.42——
Mar 24, 2025—$-0.28——
Nov 13, 2024—$-0.13——
Aug 13, 2024—$-0.64——
May 13, 2024—$-0.26——
Apr 1, 2024—$-0.26——
Nov 14, 2023—$-0.15——
Aug 3, 2023—$-0.14——
May 15, 2023—$-0.34——

Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.

Related